Bruker
Bruker Receives CE-IVD Mark for Newly Launched SARS-CoV-2 PCR Test
The FluoroType SARS-CoV-2 varID Q assay detects and quantifies virus levels while also detecting four major virus mutations to aid strain identification.
Last month, the company raised seed funding from Bruker to work on diagnostic mass spectrometry-based tests that measure changes in protein glycosylation.
Avacta Collaborating With Bruker to Evaluate MALDI-Based SARS-CoV-2 Test
The companies will determine the test's suitability as an in vitro diagnostic for SARS-CoV-2 to be run on Bruker's MALDI-TOF instruments in the UK and Europe.
Numares Collaborating With Bruker on NMR-Based Diagnostics
The company aims to transition its NMR-based platform from research to clinical use and is exploring areas including kidney and liver disease and neurology.
Bruker Gets CE-IVD Mark for Coronavirus, Flu, RSV Combo Panel
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.